March 16, 2015
MacroGenics Initiates Phase 1 Study of MGD010 for the Treatment of Autoimmune Disorders Nasdaq:MGNX
MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal…